

For Metastatic Non-Small Cell Lung Cancer (NSCLC)

Your Guide

WHAT IS TECENTRIQ?

TECENTRIQ is a prescription medicine used to treat adults with:

A type of lung cancer called non-small cell lung cancer (NSCLC).

- **TECENTRIQ may be used with bevacizumab and the chemotherapy medicines carboplatin and paclitaxel as your first treatment when your lung cancer:**
 - has spread or grown, **and**
 - is a type of lung cancer called “non-squamous NSCLC”, **and**
 - your tumor does not have an abnormal “EGFR” or “ALK” gene
- **TECENTRIQ may be used alone when your lung cancer:**
 - has spread or grown, **and**
 - you have tried chemotherapy that contains platinum, and it did not work or is no longer working, **and**
 - if your tumor has an abnormal “EGFR” or “ALK” gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working

It is not known if TECENTRIQ is safe and effective in children.

SELECT IMPORTANT SAFETY INFORMATION

Possible serious side effects with TECENTRIQ include, but are not limited to, lung problems (pneumonitis), liver problems (hepatitis), intestinal problems (colitis), hormone gland problems (especially the thyroid, adrenal glands, pancreas, and pituitary), problems in other organs, severe infections and severe infusion reactions.

Please see pages 16-17 and full [Prescribing Information](#) for additional Important Safety Information.

This guide will help explain how TECENTRIQ is thought to work, and will provide Important Safety Information. This brochure also includes a list of financial resources that might be available. Read up on some practical treatment tips that may be helpful for you and your support circle.

This brochure is not intended to replace a conversation with your doctor.

Here for you

Dealing with cancer can be difficult. It's okay to feel overwhelmed or unsure of what the future looks like. There may be ups and downs ahead. This guide is here to help you navigate your journey and provide you with support. Learn more about metastatic non-small cell lung cancer (NSCLC) and how TECENTRIQ may help. This is a great starting point to help you begin to prepare for the next steps ahead.

For more information visit



TECENTRIQ.com/NSCLCinfo

or call the Patient Resource Center:



1 (877) GENENTECH (1-877-436-3683)

The Patient Resource Center is a general help line for questions related to TECENTRIQ for patients and caregivers and is not meant to be medical advice or replace the advice of your healthcare team.

Getting Started

This brochure was made to help answer questions you may have about metastatic non-small cell lung cancer and TECENTRIQ.

3

Remember to talk to your healthcare team throughout the process. They can answer any questions you may have and make sure the treatments you receive are right for you. Find information on the following:

pages 4-5

What is non-small cell lung cancer?

What is TECENTRIQ?

pages 6-7

Understanding cancer cells & PD-L1

How is TECENTRIQ thought to work?

pages 8-9

TECENTRIQ if I haven't received chemotherapy

pages 10-11

TECENTRIQ if I've already tried chemotherapy

pages 12-13

Financial resources

pages 14-15

**Additional financial resources
Connecting with care partners**

pages 16-17

Important Safety Information about TECENTRIQ

page 18

Glossary

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg / 1050 mg
INJECTION FOR IV USE

WHAT IS NON-SMALL CELL LUNG CANCER?

Lung cancer occurs when the cells in your lungs start to grow unusually or uncontrollably. The most common type of lung cancer is called non-small cell lung cancer (NSCLC). With this type of lung cancer, unusual growth takes place inside your lungs or the lining of the airways. As more cancer cells grow they can form into a tumor. As the disease advances, it may spread to the areas around your lungs or to other parts of your body. This is called metastatic non-small cell lung cancer.

WHAT ARE SOME OF THE SYMPTOMS OF NSCLC?

The most common symptoms of lung cancer may include:

- A cough that does not go away or gets worse
- Coughing up blood or rust-colored spit
- Chest pain that may get worse when taking deep breaths, coughing or laughing
- Hoarseness
- Weight loss and loss of appetite
- Shortness of breath
- Feeling tired or weak
- Infections such as bronchitis and pneumonia that don't go away or keep coming back
- New onset of wheezing

When lung cancer spreads to distant organs (metastatic lung cancer), it can cause other symptoms which may include:

- Bone pain (like pain in the back or hips)
- Difficulty swallowing
- Swelling of the face
- Bulging veins on the neck and head
- Lumps in the neck or above the collarbone
- Yellowing of the skin and eyes
- Headache
- Weakness or numbness of an arm or a leg
- Dizziness
- Balance problems
- Seizures

Experiencing these symptoms does not necessarily mean you have lung cancer. However, it is very important to talk to your healthcare team if you experience any of these symptoms. Your healthcare team has the knowledge and the tools needed to make the appropriate diagnosis.

**FOR MORE INFORMATION ABOUT TECENTRIQ,
TALK TO YOUR HEALTHCARE TEAM**



WHAT IS TECENTRIQ?

TECENTRIQ is a prescription medicine used to treat adults with:

A type of lung cancer called non-small cell lung cancer (NSCLC).

- **TECENTRIQ may be used with bevacizumab and the chemotherapy medicines carboplatin and paclitaxel as your first treatment when your lung cancer:**

- has spread or grown, **and**
- is a type of lung cancer called “non-squamous NSCLC”, **and**
- your tumor does not have an abnormal “EGFR” or “ALK” gene

- **TECENTRIQ may be used alone when your lung cancer:**

- has spread or grown, **and**
- you have tried chemotherapy that contains platinum, and it did not work or is no longer working, **and**
- if your tumor has an abnormal “EGFR” or “ALK” gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working

It is not known if TECENTRIQ is safe and effective in children.


Please see full [Prescribing Information](#) and additional Important Safety Information throughout this brochure.

**TECENTRIQ**[®]
atezolizumab 840 mg / 1000 mg
INJECTION FOR IV USE


UNDERSTANDING CANCER CELLS & PD-L1

Your immune system helps to protect you against infection and disease. It does this through a collection of specialized organs and cells. Normally, your immune system is able to detect and remove abnormal cells, such as cancer cells.

6



Some cancer cells can go undetected by your immune system. One way they can go undetected is through a protein called programmed death-ligand 1, or PD-L1. This protein is found on many cells, including cancer cells. PD-L1 on cancer cells may bind to your immune cells. When it does this, the cancer cell is seen as a healthy cell. This may prevent your immune system from being able to recognize and attack your cancer.



HOW IS TECENTRIQ THOUGHT TO WORK?

TECENTRIQ is a cancer immunotherapy that can help reactivate the immune system so it can recognize cancer cells in the body. TECENTRIQ is an anti-PD-L1 antibody, meaning it is designed to block PD-L1. By blocking PD-L1, TECENTRIQ is thought to reveal cancer cells. This process helps your immune system recognize, target, and attack your cancer. TECENTRIQ may also affect normal cells.

SELECT IMPORTANT SAFETY INFORMATION

TECENTRIQ can cause your immune system to attack normal organs and tissues and can affect the way they work. These problems can sometimes become serious or life threatening and can lead to death.



Please see full [Prescribing Information](#) and additional Important Safety Information throughout this brochure.

 **TECENTRIQ[®]**
atezolizumab 840 mg / 1000 mg
INJECTION FOR IV USE

IF I HAVEN'T RECEIVED CHEMOTHERAPY, WHAT ARE THE POTENTIAL BENEFITS OF TECENTRIQ + OTHER MEDICINES?

8

In a clinical trial of TECENTRIQ + other medicines (bevacizumab + carboplatin + paclitaxel) that included **696 people** with metastatic non-squamous non-small cell lung cancer (NSCLC) with no abnormal EGFR or ALK gene:

PATIENTS LIVED LONGER WITH TECENTRIQ + OTHER MEDICINES*

MEDIAN OVERALL SURVIVAL (OS)[†]



*Other medicines = bevacizumab + carboplatin + paclitaxel.

[†]Median OS = The length of time from the start of treatment in a clinical trial that half of the patients are still alive.

[‡]Chemotherapy = carboplatin + paclitaxel.

PATIENTS HAD DELAYED WORSENING OF THEIR DISEASE WITH TECENTRIQ + OTHER MEDICINES

MEDIAN PROGRESSION-FREE SURVIVAL (PFS): The amount of time that half the people lived without their tumors growing or spreading was 7 months for those not taking TECENTRIQ. That time is compared with 8.5 months for those taking TECENTRIQ + other medicines.

MORE PATIENTS RESPONDED[§] ON TECENTRIQ + OTHER MEDICINES

ON BEVACIZUMAB + CHEMOTHERAPY[‡]




ON TECENTRIQ + BEVACIZUMAB + CHEMOTHERAPY



[§]In other words, the cancer was reduced or could no longer be detected on a scan. TECENTRIQ may not work for everyone.

IF I HAVEN'T RECEIVED CHEMOTHERAPY, HOW IS TECENTRIQ GIVEN?

Your healthcare provider will give you TECENTRIQ into your vein through an intravenous (IV) line. They will also decide how long you may be on treatment. If at any point the disease progresses or treatments can't be tolerated, infusions will be stopped. The first TECENTRIQ infusion is given over 60 minutes. If tolerated, the following infusions of TECENTRIQ may be given over 30 minutes. Additional time will be needed for your other medications. Ask your doctor how much time your other medications will require.



SELECT IMPORTANT SAFETY INFORMATION

TECENTRIQ can cause serious side effects, including:

- **Lung problems (pneumonitis)**—signs and symptoms of pneumonitis may include new or worsening cough, shortness of breath, and chest pain
- **Liver problems (hepatitis)**—signs and symptoms of hepatitis may include yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach area (abdomen), drowsiness, dark urine (tea colored), bleeding or bruising more easily than normal, and feeling less hungry than usual

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this brochure.


TECENTRIQ[®]
 atezolizumab 840 mg / 1050 mg
INJECTION FOR IV USE

IF I'VE ALREADY TRIED CHEMOTHERAPY, WHAT ARE THE POTENTIAL BENEFITS OF TECENTRIQ?

10

In a clinical trial of TECENTRIQ that included **850 people** with previously treated, metastatic non-small cell lung cancer (NSCLC):

PATIENTS LIVED LONGER WITH TECENTRIQ

MEDIAN OVERALL SURVIVAL (OS)*



*Median OS = The length of time from the start of treatment in a clinical trial that half of the patients are still alive
†Docetaxel.

TECENTRIQ may not work for everyone.

SELECT IMPORTANT SAFETY INFORMATION

TECENTRIQ can cause serious side effects, including:

- **Intestinal problems (colitis)**—signs and symptoms of colitis may include diarrhea (loose stools) or more bowel movements than usual, blood or mucus in your stools or dark, tarry, sticky stools, and severe stomach area (abdomen) pain or tenderness
- **Hormone gland problems (especially the thyroid, adrenal glands, pancreas, and pituitary)**—signs and symptoms that your hormone glands are not working properly may include headaches that will not go away or unusual headaches, extreme tiredness, weight gain or weight loss, dizziness or fainting, feeling more hungry or thirsty than usual, hair loss, changes in mood or behavior (such as decreased sex drive, irritability, or forgetfulness), feeling cold, constipation, your voice gets deeper, urinating more often than usual, nausea or vomiting, and stomach area (abdomen) pain

IF I'VE ALREADY TRIED CHEMOTHERAPY, HOW IS TECENTRIQ GIVEN?

Your healthcare provider will give you TECENTRIQ into your vein through an intravenous (IV) line. They will also decide how long you may be on treatment. If at any point the disease progresses or treatments can't be tolerated, infusions will be stopped.

FIRST INFUSION



The first infusion of **TECENTRIQ** is 60 minutes.




FOLLOWING INFUSIONS



If tolerated, the following infusions of **TECENTRIQ** may be 30 minutes.

FLEXIBLE INFUSION SCHEDULE

Depending on your healthcare provider recommendations and your particular situation, **TECENTRIQ** offers multiple dosing options.



**SPEAK WITH YOUR HEALTHCARE PROVIDER
TO CREATE AN INFUSION SCHEDULE FOR YOU**

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg / 1200 mg
INJECTION FOR IV USE

COMMITTED TO HELPING YOU FIND ASSISTANCE OPTIONS FOR TECENTRIQ

If you are worried about paying for TECENTRIQ, we can help you understand options that may help you. We can find out how much it will cost. We can also help you understand if there are options to help you pay for it.

TECENTRIQ ACCESS SOLUTIONS

TECENTRIQ Access Solutions is committed to helping you get the Genentech medicine your doctor prescribed.

At [Genentech-Access.com/TECENTRIQ/patients](https://www.genentech-access.com/TECENTRIQ/patients), you can:

- Find out what we offer
- Learn what to expect
- Get started with patient assistance

GENENTECH PATIENT FOUNDATION

The Genentech Patient Foundation helps people whether or not they have insurance. For more information, call a Foundation Specialist at **(888) 941-3331** or visit [GenentechPatientFoundation.com](https://www.GenentechPatientFoundation.com).

To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have exhausted all other forms of patient assistance (including TECENTRIQ Co-pay Program and support from independent co-pay assistance foundations) and must meet certain financial criteria. Uninsured patients and insured patients without coverage for their medicine must meet different financial criteria.



Please see full **Prescribing Information** and additional **Important Safety Information** throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg / 1,000 mg
INJECTION FOR IV USE

TECENTRIQ CO-PAY PROGRAM

TECENTRIQ Access Solutions can refer you to the TECENTRIQ Co-pay Program. It can help you with the out-of-pocket costs of TECENTRIQ, if you're eligible.

14

NO INCOME REQUIREMENTS	PATIENTS PAY AS LITTLE AS \$5 FOR TECENTRIQ	ANNUAL BENEFIT LIMIT OF CO-PAY PROGRAM IS \$25k
-------------------------------------	--	--

No physical card needed; patients simply need their Member ID.

To learn more about the TECENTRIQ Co-pay Program, call (855) MY-COPAY (855-692-6729) or visit copayassistancenow.com.

This TECENTRIQ Co-pay Program is valid ONLY for patients with commercial insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid, or any other federal or state government program to pay for their medications are not eligible.

Under the Program, the patient will pay a co-pay. After reaching the maximum Program benefit, the patient will be responsible for all out-of-pocket costs.

All participants are responsible for reporting the receipt of all Program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this Program. This Program is void where prohibited by law. Genentech reserves the right to rescind, revoke, or amend the Program without notice at any time. Additional eligibility criteria apply. See full terms and conditions at copayassistancenow.com.

Please visit copayassistancenow.com for the full list of terms and conditions.



CONNECTING WITH CARE PARTNERS

There will be times that you need extra help and support. It's important to know that you don't have to go through this alone. Friends, family, social workers, and support groups are just some of the people around you that may help.

It may be hard to share your feelings with your caregiver, or to ask for help. Communication with your care partner is an important step in getting the support you need. The more they know how you're feeling, the better prepared they can be to help you.

Share more information and resources with your loved one by visiting TECENTRIQ.com/NSCLC/Caregiver.

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg / 1050 mg
INJECTION FOR IV USE

IMPORTANT SAFETY INFORMATION ABOUT TECENTRIQ

What is the most important information about TECENTRIQ?

TECENTRIQ can cause your immune system to attack normal organs and tissues and can affect the way they work. These problems can sometimes become serious or life threatening and can lead to death.

Call or see your healthcare provider right away if you get any symptoms of the following problems or these symptoms get worse.

TECENTRIQ can cause serious side effects, including:

- **Lung problems (pneumonitis)**—signs and symptoms of pneumonitis may include new or worsening cough, shortness of breath, and chest pain
- **Liver problems (hepatitis)**—signs and symptoms of hepatitis may include yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach area (abdomen), drowsiness, dark urine (tea colored), bleeding or bruising more easily than normal, and feeling less hungry than usual
- **Intestinal problems (colitis)**—signs and symptoms of colitis may include diarrhea (loose stools) or more bowel movements than usual, blood or mucus in your stools or dark, tarry, sticky stools, and severe stomach area (abdomen) pain or tenderness
- **Hormone gland problems (especially the thyroid, adrenal glands, pancreas, and pituitary)**—signs and symptoms that your hormone glands are not working properly may include headaches that will not go away or unusual headaches, extreme tiredness, weight gain or weight loss, dizziness or fainting, feeling more hungry or thirsty than usual, hair loss, changes in mood or behavior (such as decreased sex drive, irritability, or forgetfulness), feeling cold, constipation, your voice gets deeper, urinating more often than usual, nausea or vomiting, and stomach area (abdomen) pain
- **Problems in other organs**—signs and symptoms may include severe muscle weakness, numbness or tingling in hands or feet, confusion, blurry vision, double vision, or other vision problems, changes in mood or behavior, extreme sensitivity to light, neck stiffness, eye pain or redness, skin blisters or peeling, chest pain, irregular heartbeat, shortness of breath, or swelling of the ankles
- **Severe infections**—signs and symptoms of infection may include fever, cough, flu-like symptoms, pain when urinating, and frequent urination or back pain
- **Severe infusion reactions**—signs and symptoms of infusion reactions may include chills or shaking, itching or rash, flushing, shortness of breath or wheezing, swelling of your face or lips, dizziness, fever, feeling like passing out, and back or neck pain

Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may delay or completely stop treatment with TECENTRIQ if you have severe side effects.

Before you receive TECENTRIQ, tell your healthcare provider about all of your medical conditions, including if you:

- have immune system problems (such as Crohn's disease, ulcerative colitis, or lupus); have had an organ transplant; have lung or breathing problems; have liver problems; have a condition that affects your nervous system (such as myasthenia gravis or Guillain-Barre syndrome); or are being treated for an infection
- are pregnant or plan to become pregnant. TECENTRIQ can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with TECENTRIQ. **Females who are able to become pregnant:**
 - your healthcare provider should do a pregnancy test before you start treatment with TECENTRIQ
 - you should use an effective method of birth control during your treatment and for at least 5 months after the last dose of TECENTRIQ
- are breastfeeding or plan to breastfeed. It is not known if TECENTRIQ passes into your breast milk. Do not breastfeed during treatment and for at least 5 months after the last dose of TECENTRIQ

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of TECENTRIQ when used in lung cancer with other anti-cancer medicines include:

- feeling tired or weak
- constipation
- nausea
- diarrhea
- hair loss
- decreased appetite

TECENTRIQ may cause fertility problems in females, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of TECENTRIQ. Ask your healthcare provider or pharmacist for more information about the benefits and side effects of TECENTRIQ.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg / 1050 mg
INJECTION FOR IV USE

GLOSSARY



ALK (anaplastic lymphoma kinase) gene:

A gene that makes a protein called anaplastic lymphoma kinase (ALK), which may be involved in cell growth.

Antibody:

A protein made by the immune system during an immune response that attaches to specific cells and can affect the immune system's ability to target and kill cells.

EGFR (epidermal growth factor receptor):

The protein found on the surface of some cells and to which epidermal growth factor binds, causing the cells to divide. It is found at abnormally high levels on the surface of many types of cancer cells, so these cells may divide excessively in the presence of epidermal growth factor.

Immune system:

A collection of organs, special cells, and substances that help protect you from infections and other diseases.

Infusion:

A method of putting fluids, including drugs, into the bloodstream. Also called intravenous infusion.

Median:

A statistics term. The middle value, or number, in a set of measurements, which have been put in order from lowest to highest.

Metastatic:

A stage in cancer where it has spread from the place where it started to other distant parts of the body.

NSCLC (non-small cell lung cancer):

A cancer that grows from inside your lungs or the lining of the airways.

Non-squamous lung cancer:

A type of lung cancer that does not start in early versions of squamous cells, which are flat cells that line the inside of the airways in the lungs.

PD-L1 (programmed death-ligand 1):

A protein found on the surface of many cells, including cancer cells, that can affect the immune system's ability to target and attack cells.

Protein:

A molecule that is the building block of the cells in the body. Proteins are needed for the body to function properly.

Source:

<http://www.cancer.gov/publications/dictionaries/cancer-terms>.

The people depicted herein are not actual patients.

YOUR NOTES

19 Use the following pages to write down any notes, questions, or concerns you would like to mention to your healthcare team.



Please see full [Prescribing Information](#) and additional Important Safety Information throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg / 1000 mg
INJECTION FOR IV USE

CAREGIVER SUPPORT

Thank you for taking an active role in your loved one's journey on TECENTRIQ®. As a caregiver, you're a vital member of the team.

Access information and resources with your loved one by visiting TECENTRIQ.com/NSCLC/Caregiver





For more information visit
TECENTRIQ.com/NSCLCinfo



or call the Patient Resource Center:
1 (877) GENENTECH (1-877-436-3683)

The Patient Resource Center is a general help line for questions related to TECENTRIQ for patients and caregivers and is not meant to be medical advice or replace the advice of your healthcare team.

Genentech
A Member of the Roche Group

© 2019 Genentech USA, Inc. All rights reserved.
PDL/082718/0137(1)

 **TECENTRIQ[®]**
atezolizumab 840 mg / 1200 mg
INJECTION FOR IV USE